[Federal Register Volume 71, Number 182 (Wednesday, September 20, 2006)]
[Notices]
[Pages 54994-54995]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-7985]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 2006E-0023 and 2006E-0345]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; MYCAMINE--New Drug Application 21-754

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined the 
regulatory review period for MYCAMINE and is publishing this notice of 
that determination as required by law. FDA has made the determination 
because of the submission of applications to the Director of Patents 
and Trademarks, Department of Commerce, for the extension of a patent 
which claims that human drug product.

ADDRESSES: Submit written comments and petitions to the Division of 
Dockets Management (HFA-305), Food and Drug Administration, 5630 
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments 
to http://www.fda.gov/dockets/ecomments.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory 
Policy (HFD-7), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-594-2041.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term 
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug 
and Patent Term Restoration Act (Public Law 100-670) generally provide 
that a patent may be extended for a period of up to 5 years so long as 
the patented item (human drug product, animal drug

[[Page 54995]]

product, medical device, food additive, or color additive) was subject 
to regulatory review by FDA before the item was marketed. Under these 
acts, a product's regulatory review period forms the basis for 
determining the amount of extension an applicant may receive.
    A regulatory review period consists of two periods of time: A 
testing phase and an approval phase. For human drug products, the 
testing phase begins when the exemption to permit the clinical 
investigations of the human drug product becomes effective and runs 
until the approval phase begins. The approval phase starts with the 
initial submission of an application to market the human drug product 
and continues until FDA grants permission to market the product. 
Although only a portion of a regulatory review period may count toward 
the actual amount of extension that the Director of Patents and 
Trademarks may award (for example, half the testing phase must be 
subtracted, as well as any time that may have occurred before the 
patent was issued), FDA's determination of the length of a regulatory 
review period for a human drug product will include all of the testing 
phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
    FDA recently approved for marketing the human drug product MYCAMINE 
(mycafungin sodium). MYCAMINE is indicated for treatment of patients 
with esophageal candidiasis and prophylaxis of Candida infections in 
patients undergoing hematopoietic stem cell transplantation. Subsequent 
to this approval, the Patent and Trademark Office received patent term 
restoration applications for MYCAMINE (U.S. Patent Nos. 6,107,458 and 
6,265,536) from Astellas Pharma, Inc., and the Patent and Trademark 
Office requested FDA's assistance in determining these patents' 
eligibility for patent term restoration. In a letter dated February 24, 
2006, FDA advised the Patent and Trademark Office that this human drug 
product had undergone a regulatory review period and that the approval 
of MYCAMINE represented the first permitted commercial marketing or use 
of the product. Shortly thereafter, the Patent and Trademark Office 
requested that FDA determine the product's regulatory review period.
    FDA has determined that the applicable regulatory review period for 
MYCAMINE is 2,546 days. Of this time, 2,221 days occurred during the 
testing phase of the regulatory review period, while 325 days occurred 
during the approval phase. These periods of time were derived from the 
following dates:
    1. The date an exemption under section 505(i) of the Federal Food, 
Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective: 
March 29, 1998. The applicant claims June 30, 2003, as the date the 
investigational new drug application (IND) became effective. However, 
FDA records indicate that the IND effective date was March 29, 1998, 
which was 30 days after FDA receipt of the original IND.
    2. The date the application was initially submitted with respect to 
the human drug product under section 505(b) of the act: April 26, 2004. 
The applicant claims April 23, 2004, as the date the new drug 
application (NDA) for MYCAMINE (NDA 21-754) was initially submitted. 
However, FDA records indicate that NDA 21-754 was initially submitted 
on April 26, 2004.
    3. The date the application was approved: March 16, 2005. FDA has 
verified the applicant's claim that NDA 21-754 was approved on March 
16, 2005.
    This determination of the regulatory review period establishes the 
maximum potential length of a patent extension. However, the U.S. 
Patent and Trademark Office applies several statutory limitations in 
its calculations of the actual period for patent extension. In its 
applications for patent extension, this applicant seeks 476 days of 
patent term extension.
    Anyone with knowledge that any of the dates as published are 
incorrect may submit to the Division of Dockets Management (see 
ADDRESSES) written or electronic comments and ask for a redetermination 
by November 20, 2006. Furthermore, any interested person may petition 
FDA for a determination regarding whether the applicant for extension 
acted with due diligence during the regulatory review period by March 
19, 2007. To meet its burden, the petition must contain sufficient 
facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th 
Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format 
specified in 21 CFR 10.30.
    Comments and petitions should be submitted to the Division of 
Dockets Management. Three copies of any mailed information are to be 
submitted, except that individuals may submit one copy. Comments are to 
be identified with the docket number found in brackets in the heading 
of this document. Comments and petitions may be seen in the Division of 
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: September 11, 2006.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. 06-7985 Filed 9-19-06; 8:45 am]
BILLING CODE 4160-01-S